Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Rosano GMC, Celant S, Olimpieri PP, Colatrella A, Onder G, Di Lenarda A, Ambrosio G, Reboldi G, Gensini GF, Colivicchi F, Russo P. Rosano GMC, et al. Among authors: olimpieri pp. Eur J Heart Fail. 2022 May;24(5):855-860. doi: 10.1002/ejhf.2490. Epub 2022 Mar 31. Eur J Heart Fail. 2022. PMID: 35303393 Free PMC article.
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Celant S, Olimpieri OM, Pane F, Iurlo A, Summa V, Corradini P, Russo P. Breccia M, et al. Among authors: olimpieri pp. Ann Hematol. 2023 May;102(5):1257-1259. doi: 10.1007/s00277-023-05168-8. Epub 2023 Mar 13. Ann Hematol. 2023. PMID: 36914888 No abstract available.
Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D'Erasmo L, Averna M, Zambon A, Catapano AL, Russo P. Arca M, et al. Among authors: olimpieri pp. J Am Heart Assoc. 2023 Nov 7;12(21):e026550. doi: 10.1161/JAHA.122.026550. Epub 2023 Oct 18. J Am Heart Assoc. 2023. PMID: 37850449 Free PMC article.
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Olimpieri O, Pane F, Iurlo A, Foggi P, Cirilli A, Colatrella A, Cuomo M, Gozzo L, Summa V, Corradini P, Russo P; AIFA’s Monitoring Registries Group. Breccia M, et al. Among authors: olimpieri o, olimpieri pp. Cancer Med. 2020 Jun;9(12):4160-4165. doi: 10.1002/cam4.3071. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319737 Free PMC article.
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M, Celant S, Olimpieri PP, Olimpieri OM, Pane F, Iurlo A, Cirilli A, Colatrella A, Gozzo L, Pugliese S, Summa V, Foggi P, Corradini P, Russo P; AIFA Monitoring Registries Group. Breccia M, et al. Among authors: olimpieri pp, olimpieri om. Ann Hematol. 2021 Feb;100(2):481-485. doi: 10.1007/s00277-021-04406-1. Epub 2021 Jan 7. Ann Hematol. 2021. PMID: 33415425
29 results